We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Abaxis Signs Exclusive Distribution Agreement with Abbott

By LabMedica International staff writers
Posted on 05 Nov 2012
Abaxis, Inc. More...
(Union City, CA, USA) signed an exclusive multiyear distribution agreement with Abbott's Point-of-Care (POC; Princeton, NJ, USA) business to market and distribute the Piccolo Xpress, a portable clinical chemistry system, and its full line of one-time user reagent discs, to the human medical market.

Abbott will have the exclusive right to distribute and sell Abaxis' Piccolo Xpress chemistry analyzer and associated consumables in the US and China (including Hong Kong). Abaxis will retain the distribution rights to current customer Catapult Health (Dallas, TX, USA) and certain segments including pharmacy and retail store clinics, shopping malls, contract research organizations (CROs), and cruise ship lines. The company will provide technical support and warranty services to support Abbott's commercial efforts.

The Piccolo Xpress provides on-the-spot chemistry results in minutes. About the size of a shoebox, health care providers use the Piccolo Xpress's easy-to-follow color touch-screen commands to perform routine multi-chemistry panels. 0.1 mL of whole blood, serum, or plasma is added directly to the single use plastic disc containing the liquid diluent and dry reagents. The disc is placed in the analyzer drawer where centrifugal and capillary forces are used to mix the reagents and sample in the disc. The Piccolo Xpress monitors the reagent reactions simultaneously using nine wavelengths, calculates the results from the absorbance data, and reports the results. The easy-to-use, low maintenance system requires no special training to operate.

Abaxis develops, manufactures, markets, and sells portable blood analysis systems for use in any human patient-care or veterinary setting to provide clinicians with rapid blood constituent measurements.

Related Links:
Abaxis
Abbott's Point-of-Care


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Steam Sterilizer
Hi Vac II Line
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.